The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy

被引：9

作者：

Boretti, Alberto ^{[1
]}

机构：

[1] Independent Scientist, Wellington

来源：

Computers in Biology and Medicine | 2024年 / 182卷

关键词：

AI-Driven; CAR T-cell therapy; CRISPR-Cas9; Genome editing; Inhibitory effects; Manufacturing costs; Personalized immunotherapy; Precise targeting; Safety;

D O I：

10.1016/j.compbiomed.2024.109137

中图分类号：

学科分类号：

摘要：

This narrative review examines the promising potential of integrating artificial intelligence (AI) with CRISPR-Cas9 genome editing to advance CAR T-cell therapy. AI algorithms offer unparalleled precision in identifying genetic targets, essential for enhancing the therapeutic efficacy of CAR T-cell treatments. This precision is critical for eliminating negative regulatory elements that undermine therapy effectiveness. Additionally, AI streamlines the manufacturing process, significantly reducing costs and increasing accessibility, thereby encouraging further research and development investment. A key benefit of AI integration is improved safety; by predicting and minimizing off-target effects, AI enhances the specificity of CRISPR-Cas9 edits, contributing to safer CAR T-cell therapy. This advancement is crucial for patient safety and broader clinical adoption. The convergence of AI and CRISPR-Cas9 has transformative potential, poised to revolutionize personalized immunotherapy. These innovations could expand the application of CAR T-cell therapy beyond hematologic malignancies to various solid tumors and other non-hematologic conditions, heralding a new era in cancer treatment that substantially improves patient outcomes. © 2024 Elsevier Ltd

引用

共 66 条

[11]

Wang H., La Russa M., Qi L.S., CRISPR/Cas9 in genome editing and beyond, Annu. Rev. Biochem., 85, pp. 227-264, (2016)

[12]

Jiang F., Doudna J.A., CRISPR–Cas9 structures and mechanisms, Annu. Rev. Biophys., 46, pp. 505-529, (2017)

[13]

Razeghian E., Nasution M.K., Rahman H.S., Gardanova Z.R., Abdelbasset W.K., Aravindhan S., Bokov D.O., Suksatan W., Nakhaei P., Shariatzadeh S., Marofi F., A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies, Stem Cell Res. Ther., 12, pp. 1-17, (2021)

[14]

Dimitri A., Herbst F., Fraietta J.A., Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing, Mol. Cancer, 21, 1, (2022)

[15]

Majzner R.G., Mackall C.L., Clinical lessons learned from the first leg of the CAR T cell journey, Nat. Med., 25, 9, pp. 1341-1355, (2019)

[16]

Guedan S., Ruella M., June C.H., Emerging cellular therapies for cancer, Annu. Rev. Immunol., 37, pp. 145-171, (2019)

[17]

Zhang H., Qin C., An C., Zheng X., Wen S., Chen W., Liu X., Lv Z., Yang P., Xu W., Gao W., Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer, Mol. Cancer, 20, pp. 1-22, (2021)

[18]

Salas-Mckee J., Kong W., Gladney W.L., Jadlowsky J.K., Plesa G., Davis M.M., Fraietta J.A., CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy, Hum. Vaccines Immunother., 15, 5, pp. 1126-1132, (2019)

[19]

Tao R., Han X., Bai X., Yu J., Ma Y., Chen W., Zhang D., Li Z., Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology, Front. Immunol., 15, (2024)

[20]

Andreu-Saumell I., Rodriguez-Garcia A., Guedan S., Genome editing in CAR-T cells using CRISPR/Cas9 technology, Cancer Immunotherapy: Methods and Protocols, pp. 151-165, (2023)

← 1 2 3 4 5 6 7 →